Retina-Vitreous
2022 , Vol 31 , Num 3
Bilateral Uveitis and Papillitis During Metastatic Melanoma Treatment with Dabrafenib and Trametinib
Associate Professor of Ophtalmology, Dr, Başkent University Adana Research Center Ophthalmology Department, Adana, Türkiye
DOI :
10.37845/ret.vit.2022.31.48
Purpose: To report a patient who developed bilateral uveitis and papillitis during dabrafenib and trametinib treatment for metastatic cutaneous
melanoma.Material and Methods: Retrospective chart review.
Results: A patient under treatment for metastatic cutaneous melanoma with dabrafenib and trametinib presented to our clinic with 1 month of bilateral visual blurring complaint. At ophthalmological examination, bilateral uveitis and papillitis were observed. After stopping dabrafenib and trametinib and initiating topical steroid administration, intraocular inflammation and papillitis improved in 2 months. Final visual acuities were 20/20 in both eyes.
Conclusion: Mitogen activated protein kinase (MAPK) inhibitors Dabrafenib anf trametinib can lead to ocular toxicity. Patients should be informed for the need of consecutive eye examinations.
Keywords : Dabrafenib; Trametinib; Uveitis; Papillitis; Melanoma